- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Tezepelumab.
Displaying page 1 of 1.
EudraCT Number: 2018-004588-30 | Sponsor Protocol Number: D5180C00011 | Start Date*: 2019-06-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Subcutaneous Tezepelumab i... | |||||||||||||
Medical condition: Severe uncontrolled asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001294-31 | Sponsor Protocol Number: D5244C00001 | Start Date*: 2022-12-06 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) | |||||||||||||
Medical condition: Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eo... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Ongoing) SK (Ongoing) ES (Ongoing) CZ (Ongoing) DK (Ongoing) GR (Ongoing) FI (Ongoing) DE (Ongoing) BE (Ongoing) NL (Ongoing) IT (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001997-52 | Sponsor Protocol Number: 20170755 | Start Date*: 2018-12-28 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined with Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis. | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) GB (GB - no longer in EU/EEA) LV (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) PL (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002069-21 | Sponsor Protocol Number: D5180C00013 | Start Date*: 2018-10-23 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled C... | |||||||||||||
Medical condition: Severe Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003078-15 | Sponsor Protocol Number: D5180C00007 | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asth... | |||||||||||||
Medical condition: Severe uncontrolled Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006691-17 | Sponsor Protocol Number: D5180C00024 | Start Date*: 2022-07-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 40-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Depend... | |||||||||||||
Medical condition: Severe Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005457-85 | Sponsor Protocol Number: D5180C00037 | Start Date*: 2022-07-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants with Severe Asthma on High-do... | |||||||||||||
Medical condition: Severe Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) BE (Ongoing) PL (Ongoing) LV (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003079-69 | Sponsor Protocol Number: D5180C00009 | Start Date*: 2018-04-26 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid ... | |||||||||||||
Medical condition: Severe Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001363-67 | Sponsor Protocol Number: D5241C00001 | Start Date*: 2019-10-22 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstru... | |||||||||||||
Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NL (Completed) FR (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002501-53 | Sponsor Protocol Number: D5180C00018 | Start Date*: 2019-05-29 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Se... | |||||||||||||
Medical condition: Severe Uncontrolled Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) AT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003286-37 | Sponsor Protocol Number: D5180C00031 | Start Date*: 2022-12-22 | |||||||||||
Sponsor Name:AstraZeneca | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent I... | |||||||||||||
Medical condition: Moderate to Severe Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003062-39 | Sponsor Protocol Number: D5242C00001 | Start Date*: 2021-03-18 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis... | |||||||||||||
Medical condition: Severe Chronic Rhinosinusitis with Nasal Polyposis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) DK (Ongoing) HU (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000554-97 | Sponsor Protocol Number: D5180C00025 | Start Date*: 2020-10-21 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥ 5 to 11 Years of Age with Mild, Moderate, or Severe Asthma | |||||||||||||
Medical condition: Mild, moderate or severe asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002759-39 | Sponsor Protocol Number: 20190194 | Start Date*: 2021-04-01 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) IT (Ongoing) ES (Ongoing) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003584-18 | Sponsor Protocol Number: KKS-307 | Start Date*: 2023-06-26 | ||||||||||||||||
Sponsor Name:Philipps University Marburg | ||||||||||||||||||
Full Title: Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia | ||||||||||||||||||
Medical condition: Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002891-35 | Sponsor Protocol Number: RECHMPL22_0123 | Start Date*: 2023-01-04 | |||||||||||
Sponsor Name:University Hospital of Montpellier | |||||||||||||
Full Title: REVErsing airway Remodelling with Tezepelumab (REVERT): a protocol for a double-blind randomized controlled trial for patients with asthma | |||||||||||||
Medical condition: exacerbating asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000179-38 | Sponsor Protocol Number: ESR-21-21168 | Start Date*: 2022-04-28 | |||||||||||
Sponsor Name:Bispebjerg Hospital | |||||||||||||
Full Title: Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of tezepelumab | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005542-56 | Sponsor Protocol Number: ESR-15-10870 | Start Date*: 2016-04-29 | |||||||||||
Sponsor Name:Copenhagen University Hospital Bispebjerg | |||||||||||||
Full Title: Effects of anti-TSLP on airway hyperresponsiveness and mast cell phenotype in asthma - A randomized double-blind, placebo-controlled trial of MEDI9929 The UPSTREAM study | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.